Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 2.56
- Piotroski Score 5.00
- Grade Buy
- Symbol (DVAX)
- Company Dynavax Technologies Corporation
- Price $12.38
- Changes Percentage (1.68%)
- Change $0.21
- Day Low $12.11
- Day High $12.45
- Year High $15.01
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/20/2025
- Fiscal Year End N/A
- Average Stock Price Target $24.50
- High Stock Price Target $29.00
- Low Stock Price Target $20.00
- Potential Upside/Downside N/A
- Consensus Rating Buy
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $0.07
- Trailing P/E Ratio 172.29
- Forward P/E Ratio 172.29
- P/E Growth 172.29
- Net Income $-6,389,000
Income Statement
Quarterly
Annual
Latest News of DVAX
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Dynavax Technologies (DVAX) Q2 2024 Earnings Call Transcript
Dynavax Technology's second-quarter 2024 financial results call discussed record HEPLISAV-B sales and pipeline progress. The company reaffirmed its 2024 revenue guidance and long-term market growth pr...
By Yahoo! Finance | 3 months ago
